Prognostic factors and fertility outcomes of borderline ovarian tumors after conservative surgery / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 488-492, 2010.
Article
Dans Chinois
| WPRIM
| ID: wpr-322744
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the prognostic factors and fertility outcomes of borderline ovarian tumors (BOT) after conservative surgery.</p><p><b>METHODS</b>The clinical data of 109 patients with BOT who were treated in Peking Union Medical College Hospital from January 1990 to December 2007 were retrospectively analyzed. According to the FIGO staging system,there were 34(31.2%) patients at Stage Ia and Ib, 66 (60.6%) at Stage Ic, 2 (1.8%) at Stage II and 7(6.4%) at stage III. No patient was at Stage 4.</p><p><b>RESULTS</b>Surgical treatment included comprehensive staging surgery (n=40, 36.7%), ovarian cystectomy (n=27,24.8%), and unilateral salpingo-ovariectomy (n=42, 38.5%). The average follow-up period was (60.3±42.5) months. Relapse occurred in 25 patients (22.9%), and the mean duration from therapy to recurrence was (36.1±31.9) months. Only one patient died of BOT. Multivariate analysis showed that surgery procedure and tumor stage were the independent prognostic factors affecting recurrence. Of 66 patients with the desire of fertility, 24 (36.4%) finally got pregnant.</p><p><b>CONCLUSIONS</b>Conservative surgery has comparatively good prognosis and should be the first choice for younger patients with the desire of fertility. The high-risk factors should be evaluated before the initiation of treatment.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de l'ovaire
/
Pronostic
/
Chirurgie générale
/
Études rétrospectives
/
Études de suivi
/
Résultat thérapeutique
/
Tumeurs épithéliales épidermoïdes et glandulaires
/
Fécondité
Type d'étude:
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adolescent
/
Adulte
/
Femelle
/
Humains
langue:
Chinois
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS